Table 4 Results, summary of the judgements made by the 17 evaluators of the quality for each of the outcomes presented in the 12 examples in the pilot study.
Outcome | High | Moderate | Low | Very low | Consensus | Comments |
|---|---|---|---|---|---|---|
Depression severity | 6/17 | 10/17 | - | - | Moderate | |
Transient side effects | 7/17 | 10/17 | - | - | High | Changed to little uncertainty |
Poisoning fatalities | - | 4/17 | 7/17 | 6/17 | Moderate | Upgraded for very strong association |
Stroke | 15/17 | 2/17 | - | - | High | |
Extracranial hemorrage | 16/16 | - | - | - | High | |
All cause mortality | 12/17 | 5/17 | - | - | - | Agreed to remove this outcome |
Pain at rest | 16/17 | 1/17 | - | - | High | |
Pain ay motion | 15/17 | 2/17 | - | - | Moderate | Uncertainty about directness of outcome measure |
Mobility | 3/17 | 14/17 | - | - | Moderate | |
Quality of life | 1/17 | 11/17 | 5/17 | - | Moderate | |
Dropout due to side effects | 14/17 | 3/17 | - | - | High | |
Serious gi complications | - | 3/17 | 8/17 | 6/17 | - | Need more information before consensus |
All cause mortality | 2/17 | 15/17 | - | - | Moderate | |
Non-fatal stroke | 17/17 | - | - | - | High | |
Non-fatal MI | 17/17 | - | - | - | High | |
Death | 13/17 | 4/17 | - | - | High | |
Non-fatal MI | 11/16 | 5/16 | - | - | High | |
All cause death | 12/17 | 5/17 | - | - | Moderate | If reporting bias, otherwise high |
Major bleeding | 15/17 | 2/17 | - | - | High | |
Recurrent thromboembolism | 6/17 | 11/17 | - | - | High | |
Clinical cure | - | 13/17 | 4/17 | - | Moderate | |
Dropout due to side effects | - | 10/17 | 7/17 | - | Moderate | |
Relapse | 2/17 | 11/17 | 4/17 | - | Moderate | |
Tuberculosis | 2/17 | 10/17 | 5/17 | - | Moderate | |
TB death | 8/17 | 8/17 | 1/17 | - | High | |
TB meningitis | 1/17 | 4/17 | 12/17 | - | Moderate | Strong association |
Serious adverse events | 1/12 | - | - | 11/12 | - | No data, outcome removed |
Condition unchanged | 5/17 | 19/17 | 2/17 | - | - | No consensus regarding sparse data |
Poor outcome- surgeon rated | 9/17 | 8/17 | - | - | - | Need bias information before consensus |
2nd procedure needed | 9/17 | 8/17 | - | - | Moderate | |
No success – objective rater | 5/17 | 10/17 | 2/17 | - | - | No consensus regarding sparse data |
Risks & side effects | 1/15 | 2/15 | 2/15 | 10/15 | - | No data, outcome removed |
Dental caries – start | - | - | 8/17 | 9/17 | Very low | |
Dental caries – stop | - | - | 5/17 | 12/17 | Very low | |
Dental florosis | - | 1/17 | 3/17 | 13/17 | Very low | |
Bone fracture | - | 1/17 | 3/17 | 13/17 | Very low | |
Cancer mortality | - | 1/17 | 2/17 | 14/17 | Very low | |
All injuries | - | 1/17 | 12/17 | 4/17 | Very low | Question changed |
Correct use early | 8/17 | 5/17 | 4/17 | - | High | Question changed |
Correct use follow up | 2/17 | 8/17 | 6/17 | 1/17 | High | Question changed |
Possession of seat | 7/17 | 6/17 | 3/17 | - | High | Question changed |
CHD | 11/13 | 2/13 | - | - | High | |
Breast cancer | 11/13 | 2/13 | - | - | High | |
Stroke | 11/13 | 2/13 | - | - | High | |
Colorectal cancer | 11/13 | 2/13 | - | - | High | |
Endometrial cancer | 11/13 | 2/13 | - | - | High | |
Hip fracture | 11/13 | 2/13 | - | - | High |